World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
Posts
#FindingsFriday: Can genetics help predict who develops immune-related side effects from #immunotherapy? This study by @ATarhiniMDPhD & colleagues shows polygenic risk scores may help identify patients at higher risk of thyroiditis. More in @jitcancer:
Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma
Background Inherited genetic variation may impact patient response and risk of toxicity following immune checkpoint inhi...
bit.ly
We extend our deepest condolences to Dr. Gillison's family and to the many in our community who mourn her loss.
Please see our message regarding the passing of Dr. Maura Gillison. Our thoughts are with her family, friends, and loved ones during this difficult time. Read the message here: https://conta.cc/4euSx8O
#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: https://bit.ly/mm1oa-ea02-study
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
32
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
